<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018131</url>
  </required_header>
  <id_info>
    <org_study_id>0071</org_study_id>
    <nct_id>NCT04018131</nct_id>
  </id_info>
  <brief_title>The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy</brief_title>
  <official_title>The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy, a Study of Immunoglobulin E, Interleukin-4, Interleukin-12, and Interferon-Ɣ Serum Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extrinsic - atopic dermatitis is characterized by increased of IgE serum levels. Acute&#xD;
      extrinsic - atopic dermatitis is a type 1 hypersensitivity that involve various inflammatory&#xD;
      mediator including Interleukin-4, Interleukin-12, and Interferon-Ɣ. Recent treatment of&#xD;
      atopic dermatitis mainly focused on reducing the inflammation through topical and systemic&#xD;
      regiments. However, no systemic medication could control the atopic dermatitis remission yet,&#xD;
      and the current immunosuppressive agent used may cause many side effects if administered on a&#xD;
      long term basis.&#xD;
&#xD;
      In the future, treatment of atopic dermatitis were specifically targeted to inhibit the role&#xD;
      of Th2. Cimetidine is H2 receptor antihistamine that has been widely used as gastrointestinal&#xD;
      medication for a long time. Cimetidine could modulate the immune system by activating the Th1&#xD;
      and lowering the Th2 activity, and lowering the IgE levels thus reducing the severity of&#xD;
      atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to measure the efficacy of cimetidine for acute, extrinsic-atopic&#xD;
      dermatitis treated with standard therapy using SCORAD as the clinical outcome. This study&#xD;
      also measure Immunoglobulin E, Interleukin-4, Interleukin-12, and Interferon-Ɣ serum levels&#xD;
      before and after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SCORAD change</measure>
    <time_frame>0, 2, 4, 6, 8 weeks</time_frame>
    <description>Scoring Atopic Dermatitis (SCORAD) is a score to indicate the severity of atopic dermatitis.&#xD;
The minimum score is 0, maximum score is 103. Mild 0 - 14 Moderate 15 - 39 Severe 40 - 103&#xD;
The SCORAD before treatment was expected to be higher than after treatment. Outcome: change of SCORAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunoglobulin E change</measure>
    <time_frame>0, 8 weeks</time_frame>
    <description>Change of Immunoglobulin E</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-4 change</measure>
    <time_frame>0, 8 weeks</time_frame>
    <description>Change of Interleukin-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-12 change</measure>
    <time_frame>0, 8 weeks</time_frame>
    <description>Change of Interleukin-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon Gamma change</measure>
    <time_frame>0, 8 weeks</time_frame>
    <description>Change of Interferon Gamma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Immunoglobulin E Concentration, Serum</condition>
  <arm_group>
    <arm_group_label>Cimetidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimetidine</intervention_name>
    <description>Antihistamine 2 antagonist</description>
    <arm_group_label>Cimetidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Atopic dermatitis patients diagnosed with Hanifin Rajka criteria&#xD;
&#xD;
          -  Acute extrinsic atopic dermatitis&#xD;
&#xD;
          -  IgE levels above 200 IU/mL&#xD;
&#xD;
          -  Minimum weight 15kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consumption of corticosteroid and systemic immunosuppressant within the last 2 weeks&#xD;
&#xD;
          -  Chronic lesion&#xD;
&#xD;
          -  Consumption of drugs that reacts with cimetidine&#xD;
&#xD;
          -  Disturbance in lab results including complete blood count, liver function, and renal&#xD;
             function.&#xD;
&#xD;
          -  Other conditions that might increase IgE levels&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Endi Novianto</last_name>
    <phone>+628161309063</phone>
    <email>drendinovianto@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Universitas Indonesia</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Endi Novianto, MD</last_name>
      <phone>+628161309063</phone>
      <email>drendinovianto@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Cimetidine</keyword>
  <keyword>Immunoglobulin E</keyword>
  <keyword>Interleukin-4</keyword>
  <keyword>Interleukin-12</keyword>
  <keyword>Interferon Gamma</keyword>
  <keyword>SCORAD</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

